Impact of dyslipidemia associated with highly active antiretroviral therapy (HAART) on cardiovascular risk and life expectancy

American Journal of Cardiology

Volumn 95, Issue 5, 2005, Pages 586-591

  Grover, Steven A ^a   Coupal, Louis ^b   Gilmore, Norbert ^b   Mukherjee, Jayanti ^b  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; CHOLESTEROL; LAMIVUDINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NELFINAVIR; PROTEINASE INHIBITOR; STAVUDINE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; DYSLIPIDEMIA; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPERCHOLESTEROLEMIA; LIFE EXPECTANCY; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROBABILITY; PROTEINASE INHIBITION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE;

EID: 13844255117     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2004.11.004     Document Type: Article

References (30)

1. K. Henry, H. Melroe, J. Huebsch, J. Hermundson, C. Levine, L. Swensen, J. Daley Severe premature coronary artery disease with protease inhibitors Lancet 351 1998 1328
2. B. Gallet, M. Pulik, P. Genet, P. Chedin, M. Hiltgen Vascular complications associated with use of HIV protease inhibitors Lancet 351 1998 1959
3. R.L. Murphy, I. Sanne, P. Cahn, P. Phanuphak, L. Percival, T. Kelleher, M. Giordano Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results AIDS 17 2003 2603 2614
4. S.A. Grover, S. Paquet, C. Levinton, L. Coupal, H. Zowall Estimating the benefits of modifying risk factors of cardiovascular disease A comparison of primary vs secondary prevention Arch Intern Med 158 1998 655 662
5. K.M. Anderson, P.W.F. Wilson, P.M. Odell, W.B. Kannel An updated coronary risk profile A statement for health professionals Circulation 83 1991 356 362
6. G. Heiss, I. Tamir, C.E. Davis, H.A. Tyroler, B.M. Rifkind, G. Schonfeld, D. Jacobs, J. Frantz Lipoprotein-cholesterol distributions in selected North American populations: the Lipid Research Clinics Program Prevalence Study Circulation 61 1980 302 315
7. Lipid Research Clinics Program The Lipid Research Clinics Coronary Primary Prevention Trial results II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering JAMA 251 1984 365 374
8. V. Manninen, O. Elo, H. Frick, K. Haapa, O.P. Heinonen, J.K. Huttunen, P. Kaitaniemi, P. Koskinen Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study JAMA 260 1988 641 651
9. J. Shepherd, S.M. Cobbe, I. Ford, C.G. Isles, A.R. Lorimer, P.W. Macfarlane, J.H. McKillop, C.J. Packard West of Scotland Coronary Prevention Study Group Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia N Engl J Med 323 1990 946 955
10. T.R. Pedersen, J. Kjekshus, K. Berg Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
11. F.M. Sacks, M.A. Pfeffer, L.A. Moye, J.L. Rouleau, J.D. Rutherford, T.G. Cole, L. Brown, J.W. Warnica, J.M. Arnold, C.C. Wun The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels N Engl J Med 335 1996 1001 1009
12. H. Buchwald, R.L. Varco, J.P. Matts POSCH Group Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia N Engl J Med 323 1990 946 955
13. SHEP Cooperative Research Group Prevention of stroke antihypertensive drug treatment in older persons with isolated systolic hypertension JAMA 265 1991 255 264
14. J. Wikstrand, I. Warnold, G. Olsson, J. Tuomilheto, D. Elmfeldt, G. Berglund Primary prevention with metoprolol in patients with hypertension JAMA 259 1988 1976 1982
15. The Multiple Risk Factor Intervention Trial Research Group Mortality rates after 10.5 years for participants in the Multipile Risk Factor Intervention Trial: findings related to a priori hypothesis of the trial JAMA 263 1990 1795 1801
16. National Center for Health Statistics. Third National Health and Nutrition Examination Survey, 1988-1994. Series 11, No. 1A, ASCII version (CD ROM). NHANES III. Hyattsville, MD: Centers for Disease Control and Prevention, 1997.
17. Anderson RN. Method for Constructing Complete Annual U.S. Life Tables. Series 129. Vital and Health Statistics. Washington, DC: National Center for Health Statistics, 1999.
18. R.S. Hogg, B. Yip, K.J. Chan, E. Wood, K.J.P. Craib, M.V. O'Shaughnessy, J.S.G. Montaner Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy JAMA 286 2001 2568 2577
19. S. Tsiodras, C. Mantzoros, S. Hammer, M. Samore Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study Arch Intern Med 160 2000 2050 2056
20. N. Friis-Møller, R. Weber, P. Reiss, R. Thiébaut, O. Kirk, A. d'Arminio Monforte, C. Pradier, L. Morfeldt, S. Mateu, M. Law DAD Study Group Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy Results from the DAD study AIDS 17 2003 1179 1193
21. A. Carr, K. Samaras, A. Thorisdottir, G.R. Kaufmann, D.J. Chisholm, D.A. Cooper Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor- associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study Lancet 353 1999 2093 2099
22. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
23. J. Tsevat, M.C. Weinstein, L.W. Williams, A.N. Tosteson, L. Goldman Expected gains in life expectancy from various coronary heart disease risk factor modifications Circulation 83 1991 1194 1201
24. S.A. Grover, K. Gray-Donald, L. Joseph, M. Abrahamowicz, L. Coupal Life expectancy following dietary modification or smoking cessation: estimating the benefits of a prudent lifestyle Arch Intern Med 154 1994 1697 1704
25. G. Behrens, A. Dejam, H. Schmidt, H.J. Balks, G. Brabant, T. Korner, M. Stoll, R.E. Schmidt Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors AIDS 13 1999 F63 F70
26. A.M. Cattelan, M. Trevenzoli, L. Sasset, L. Rinaldi, V. Balasso, P. Cadrobbi Indinavir and systemic hypertension AIDS 15 2001 805 807
27. S.A. Riddler, E. Smit, S.R. Cole, R. Li, J.S. Chmiel, A. Dobs, F. Palella, B. Visscher, R. Evans, L.A. Kingsley Impact of HIV infection and HAART on serum lipids in men JAMA 289 2003 2978 2982
28. J.H. Stein, M.A. Klein, J.L. Bellehumeur, P.E. McBride, D.A. Wiebe, J.D. Otvos, J.M. Sosman Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction Circulation 104 2003 257 262
29. V. Schächinger, M.B. Britten, A.M. Zeiher Prognostic impact of coronary vasodilator dysfunctions on adverse long-term outcome of coronary heart disease Circulation 101 2000 1899 1906
30. M. Law, N. Friis-Møller, R. Weber, P. Reiss, R. Thiebault, O. Kirk, A. d'Arminio Monforte, C. Pradier, L. Morfeldt, G. Calvo DAD Study Group Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study HIV Med 4 2003 1 10